LOGIN  |  REGISTER
Assertio
Assertio

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024

March 05, 2024 | Last Trade: US$10.96 1.04 10.48

ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the fourth quarter and year ended December 31, 2023, after the close of the market on Wednesday, March 13, 2024. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions.

Wednesday, March 13, 4:30 PM EST
Domestic: 877-407-8835
International: located here
Conference ID: 13744117
Webcast: electroCore Earnings Webcast

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

For more information, visit www.electrocore.com.

Contact:
ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB